Exubera professional ads
Aventis and Pfizer name Lally McFarland & Pantello as agency of record for inhaled insulin product Exubera, currently in Phase III. LM&P will be responsible for professional ads worldwide. The agency has worked previously with Aventis on hormone replacement therapy CombiPatch (estradiol/norethindrone), and is currently working with Pfizer/Pharmacia on the second-generation COX-2 inhibitor valdecoxib
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth